Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC). This phase III study was conducted to confirm the phase II results and to detect an overall survival (OS) benefit.
Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC). This phase III study was conducted to confirm the phase II results and to detect an overall survival (OS) benefit.
Patients and Methods
Men with chemotherapy-naïve mCRPC and evidence of bone metastases were assigned (2:1) to receive tasquinimod once per day or placebo until progression or toxicity. The primary end point was radiographic PFS (rPFS; time from random assignment to radiologic progression or death) per Prostate Cancer Working Group 2 criteria and RECIST 1.1. The study had 99.9% power to detect an rPFS hazard ratio (HR) of 0.6 with a two-sided alpha error of .05 and 80% power to detect a target HR of 0.8 for OS, the key secondary end point.
Results
In all, 1,245 patients were randomly assigned to either tasquinimod (n = 832) or placebo (n = 413) between March 2011 and December 2012 at 241 sites in 37 countries. Baseline characteristics were balanced between groups: median age, 71 years; Karnofsky performance status $ 90%, 77.3%; and visceral metastases, 21.1%. Estimated median rPFS by central review was 7.0 months (95% CI, 5.8 to 8.2 months) with tasquinimod and 4.4 months (95% CI, 3.5 to 5.5 months) with placebo (HR, 0.64; 95% CI, 0.54 to 0.75; P , .001). Median OS was 21.3 months (95% CI, 19.5 to 23.0 months) with tasquinimod and 24.0 months (95% CI, 21.4 to 26.9 months) with placebo (HR, 1.10; 95% CI, 0.94 to 1.28; P = .25). Grade $ 3 adverse events were more frequent with tasquinimod (42.8% v 33.6%), the most common being anemia, fatigue, and cancer pain.
Conclusion
In chemotherapy-naïve men with mCRPC, tasquinimod significantly improved rPFS compared with placebo. However, no OS benefit was observed.
INTRODUCTION
Treatment options for metastatic castrationresistant prostate cancer (mCRPC) have expanded with the introduction of several new agents that delay disease progression and improve overall survival (OS). These include second-generation androgen-directed therapies, radium-223, sipuleucel-T, and the taxanes cabazitaxel and docetaxel. Despite these advances, mCRPC remains incurable, and survival benefits typically achieved with newer agents are modest while resistance remains common. [1] [2] [3] [4] [5] [6] [7] New agents with alternative mechanisms of action that further improve survival while minimizing toxicity are needed.
The tumor microenvironment is increasingly recognized as playing a major role in the formation and growth of metastases. 8 In addition, the host microenvironment has been shown to promote prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. 9 Drugs that target the tumor microenvironment therefore offer a potentially new approach in the treatment of advanced prostate cancer. 10 Tasquinimod (ABR-215050; Active Biotech, Lund, Sweden) is an oral immunotherapy with demonstrated effects on the tumor microenvironment that counteract tumor growth. 11, 12 One molecular target of tasquinimod is the immunomodulatory protein S100A9, which plays a role in the accumulation and function of innate immune cells, specifically regulatory myeloid cells. [11] [12] [13] Targeting regulatory myeloid cells within the tumor microenvironment leads to decreased immune suppression and angiogenesis and prevention of metastasis development. Tasquinimod may also reduce angiogenesis by downregulation of HIF1-controlled genes via interaction with histone deacetylases.
14 In a randomized, placebo-controlled phase II study in men with mCRPC, tasquinimod significantly improved progressionfree survival (PFS; median, 7.6 v 3.3 months; hazard ratio [HR], 0.57; P , .01). 15 In long-term follow-up, multivariate analysis indicated that the PFS improvement may be associated with improved OS, particularly in patients with bone metastases. 16 The objective of this phase III study was to confirm the benefit of tasquinimod in delaying disease progression and improving OS in men with mCRPC.
PATIENTS AND METHODS

Patients
Eligible patients had histologically confirmed prostate adenocarcinoma with evidence of bone metastases, serum testosterone # 50 ng/dL, disease progression (increasing serum prostate-specific antigen [PSA] as defined by the Prostate Cancer Working Group 2 [PCWG2], 17 progression of soft tissue metastasis, or bone disease progression), and Karnofsky performance status $ 70%. Concurrent use of luteinizing hormonereleasing hormone agonists or antagonists and bone agents (denosumab or bisphosphonates) was permitted.
No cytotoxic chemotherapy within 2 years or previous anticancer therapy within 4 weeks (2 weeks for sipuleucel-T) of random assignment was allowed. Prior enzalutamide or abiraterone was permitted. Other exclusion criteria included presence of prostate cancer pain requiring opiate analgesics, systemic exposure to ketoconazole, and ongoing corticosteroid treatment equivalent to a prednisolone or prednisone dose of . 10 mg/day.
Study Design
This multinational, randomized, double-blind, placebo-controlled phase III study was conducted at 241 sites in 37 countries (Appendix Table  A1 , online only). Patients were randomly assigned in a 2:1 ratio to receive tasquinimod or placebo by using an interactive voice response system. Random assignment was stratified by Karnofsky performance status ($ 90% v , 90%), presence or absence of visceral disease (all metastatic soft tissue except lymph nodes and local recurrence), and geographic region (North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America). Tasquinimod or placebo was administered orally at a starting dose of 0.25 mg/day for at least 2 weeks. 18 If tolerability was established, the dose was escalated to 0.5 mg/day for 2 weeks and then to 1 mg/day. Patients unable to tolerate the escalated doses could continue in the study at their maximum tolerated dose. Treatment continued until symptomatic disease progressed so that it required alternative antitumor therapy or until poor tolerability occurred. After the end of treatment, patients continued follow-up with visits every 3 months until death or until 727 patients had reached the survival end point.
The study was approved by the institutional review boards or ethics committees at each participating center and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent before study entry.
End Points
The primary end point was radiographic PFS (rPFS), the time from random assignment to radiologic progression or death, whatever the cause. Radiographic progression was defined as soft tissue progression (RECIST 1.1), 19 bone progression detected with confirmatory bone scans (PCWG2), 7 or radiographically confirmed spinal cord compression or fracture as a result of malignant progression. Soft tissue lesions were evaluated by computed tomography or magnetic resonance imaging scans by the investigator. All scans underwent independent central review, with reviewers blinded to study treatment and investigator assessments.
The key secondary end point was OS, defined as time from random assignment to death. Other prespecified secondary end points included time to radiologic progression, time to symptomatic progression, time to PSA progression, time to initiation of further cytotoxic therapy, time to opiate use, and time to deterioration of quality-of-life (QoL) measure (Functional Assessment of Cancer Therapy-Prostate [FACT-P]). Safety was assessed on the basis of physical examination, vital signs measurements, clinical laboratory analyses, and adverse events (AEs; coded using Medical Dictionary for Regulatory Activities [MedDRA]; graded using Common Terminology Criteria for Adverse Events [CTCAE] version 4.0).
Statistical Analysis
The planned sample size of 1,200 patients (800 in the tasquinimod arm and 400 in the placebo arm) provided 99.9% power at a two-sided significance level of 0.05 to detect an HR of 0.6 for the primary end point of rPFS, corresponding to an increase in median PFS from 3.4 to 5.7 months. The study was also designed to detect an HR of 0.8 for the key secondary end point of OS, corresponding to an increase in median OS from 22 to 27.5 months. Specifying a two-sided significance level of 0.05, the study had 80% power to detect the OS difference after 727 deaths had been observed. The OS end point comparisons incorporated group sequential design involving two interim analyses (at 473 and 582 events) and a final analysis at 727 events using O'Brien-Fleming stopping boundaries 20 : first interim analysis, P # .0109; second interim analysis, P # .0212; and final analysis, P # .0422. rPFS was analyzed at the first planned interim analysis for OS (after 473 events). If the comparison of rPFS reached statistical significance (P # .05), the first comparison of OS was performed; however, the results were not reported until the final analysis.
A stratified log-rank test by factors at random assignment was used to compare rPFS, OS, and the time-to-event secondary end points for tasquinimod versus placebo (analysis of PSA doubling time was not stratified). To describe time-to-event variables, Kaplan-Meier curves and life tables by treatment group were generated, and CIs were calculated.
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Patients who did not experience an event were censored at the date of their last adequate assessment, previous assessment, last visit, or death, depending on the end point and analysis. Treatment effect was estimated by calculating the HR and its 95% CI from a Cox proportional hazards model stratified by factors at random assignment. For rPFS and OS, Cox proportional hazards models were performed for predefined subgroups and multivariate analyses. In the latter analyses, after testing each prespecified prognostic factor with a univariate analysis, a backward selection approach was used. Treatment was always included in the models.
All efficacy end points were analyzed by planned treatment in the intent-to-treat population (all randomly assigned patients, regardless of whether any study treatment dosing was completed). The safety analysis population comprised all patients who received at least one dose of study treatment. Safety was analyzed according to treatment received. All statistical analyses were performed by using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient Disposition
Of 1,645 patients screened, 1,245 were randomly assigned to receive tasquinimod (n = 832) or placebo (n = 413) between March 29, 2011, and December 7, 2012 (Appendix Table A1 ). Two patients from each group did not receive treatment after random assignment (Fig 1) . Baseline characteristics were generally well balanced between the groups (Table 1) . A greater proportion of patients in the tasquinimod group had higher levels of baseline tumor pain (Visual Analog Scale . 4: 18.6% v 14.5%). Median time since diagnosis was shorter in the tasquinimod group than in the placebo group (45.7 v 57.7 months).
At final analysis (cutoff date: February 13, 2015), median follow-up was 30.0 months in the tasquinimod arm and 30.7 months in the placebo arm, and 96.1% of patients had discontinued treatment. The most common reasons for discontinuation (tasquinimod v placebo) were radiographic progression (23.8% v 36.5%), symptomatic progression requiring new anticancer therapy (21.3% v 18.8%), and poor tolerability or AEs (17.9% v 8.8%; Fig 1) .
Efficacy
The final analysis of the primary end point of rPFS was performed at the time of the first interim analysis of OS. Radiographic progression by central review, or death, occurred in 396 patients (48%) in the tasquinimod group and in 258 patients (62%) in the placebo group. Estimated median rPFS was 7.0 months (95% CI, 5.8 to 8.2 months) for tasquinimod and 4.4 months (95% CI, 3.5 to 5.5 months) months for placebo, corresponding to a 36% reduction in the risk of radiographic progression or death with tasquinimod versus placebo (HR, 0.64; 95% CI, 0.54 to 0.75; P ,.001; Fig 2A) . Similar results were seen in the assessment by local review: estimated median rPFS was 5.7 months (95% CI, 5.5 to 6.2 months) and 4.1 months (95% CI, 3.1 to 5.1 months), respectively (HR 0.69; 95% CI, 0.60 to 0.80; P , .001).
OS results were not significant at either of the two interim analyses and, because no safety concerns were raised, the Data and Safety Monitoring Board recommended continuation of the study according to the protocol. At final analysis of OS, 492 deaths (59.1%) had occurred in the tasquinimod group and 238 deaths (57.6%) had occurred in the placebo group. Tas Fig 2B) . The rPFS and OS results were consistent when examined across predefined patient subgroups without evidence of significant heterogeneity (Fig 3) .
In general, secondary end points that favored tasquinimod over placebo included the radiographic-and PSA-based outcomes (Table 2 and Appendix Table A2 , online only). In contrast, symptomatically assessed end points, such as time to symptomatic progression, time to opiate use, and deterioration in QoL, favored placebo. Time to initiation of salvage therapy was longer with tasquinimod than with placebo (11.4 v 8.1 months; P = .001), as was time to initiation of further cytotoxic therapy (25. 
Drug Exposure and Safety
Overall median treatment duration was 137 days (range, 1 to 1,377 days) for tasquinimod and 133 days (range, 8 to 1,179 days) for placebo, and most patients (82% and 92%, respectively) escalated to the maximum dose of 1 mg/day.
The proportion of patients with at least one dose reduction from maximum dose was higher in the tasquinimod group than in the placebo group (17.5% v 5.6% for the 1 mg/day dose and 1.4% v 0% for the 0.5 mg/day dose). The majority of patients in both treatment groups experienced at least one treatment-emergent AE (Table 3) . A greater proportion of patients in the tasquinimod group discontinued treatment because of AEs (17.7% v 10.2%), mainly as a result of decreased appetite, fatigue, asthenia, or nausea. Kaplan-Meier analysis of (A) radiologic progression-free survival (rPFS; central review) and (B) overall survival (OS). HR, hazard ratio; TASQ, tasquinimod.
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The most common reported AEs were GI disorders (60.2% for the tasquinimod group v 47.9% for the placebo group), general disorders and administration site conditions (55.1% v 39.9%), and musculoskeletal and connective tissue disorders (48.2% v 36.7%). The most frequently reported AEs are summarized in Table 3. A total of 229 patients (27.6%) in the tasquinimod group and 97 patients (23.6%) in the placebo group experienced at least one serious AE, the most common being renal and urinary disorders (7.3% v 7.3%), infections and infestations (5.1% v 4.1%), and blood and lymphatic system disorders (4.3% v 4.1%). NOTE. Time to skeletal-related events and time to symptomatic progression as a result of skeletal-related events could not be calculated because of the low number of events.
Abbreviations: FACT-P, Functional Assessment of Cancer Therapy-Prostate; HR, hazard ratio; NR, not reached; PSA, prostate-specific antigen. *Including death as a result of prostate cancer. †Including radionuclide, chemotherapy, or radiation therapy. ‡Deterioration event was classified as the first of (1) death as a result of prostate cancer, (2) significant and meaningful decline in FACT-P total score, or (3) disease progression, defined as radiologic progression and a missing FACT-P at the same scheduled visit.
The incidence of vascular disorders was similar for the tasquinimod and placebo groups (12.4% v 13.1%), as was the incidence of deep vein thrombosis (0.7% v 1.5%). Cardiac disorders were more frequent with tasquinimod (all grades, 10% v 6.8%; grades 3 to 5, 3.4% v 1.6%; serious AEs, 3.9% v 1.9%). The frequencies of specific cardiac events for tasquinimod and placebo groups, respectively, were atrial fibrillation (2.8% v 0.7%), angina pectoris (1.2% v 0.7%), cardiac failure (1.2% v 0.2%), pericardial effusion (0.8% v 0%), pericarditis (0.4% v 0%), coronary artery disease (0.4% v 0%), and myocardial infarction (0.5% v 0.2%). The incidence of death as a result of AEs was similar between the groups: 27 patients (3.3%) in the tasquinimod group and 15 patients (3.6%) in the placebo group. There were four (0.5%) cardiac AE-related deaths in the tasquinimod group and one (0.2%) in the placebo group.
DISCUSSION
Tasquinimod was shown in a randomized phase II study to improve PFS in patients with mCRPC, and it was further indicated that this effect might be associated with an OS benefit.
15,16 The primary objective of this phase III study was to confirm the phase II findings, and therefore a similar design was used with rPFS as the primary end point. However, the study was designed with sufficient statistical power to detect a potential OS benefit, and OS was the main secondary end point. The results showed that rPFS was significantly delayed by tasquinimod (36% reduced risk of radiographic progression or death v placebo, by central review; HR, 0.64), thereby confirming the phase II findings. There was good agreement between independent radiologists and local investigator assessment, suggesting that rPFS can be reliably ascertained, and recent data suggest that delays in rPFS may be associated with prolonged survival. 22 However, the significant rPFS benefit with tasquinimod did not translate into improved survival over time. Subgroup analyses demonstrated consistent results for rPFS and OS and did not highlight any clear heterogeneity for an OS benefit among any of the subgroups. Tasquinimod seemed to provide clinical benefit over placebo with respect to a number of other objective radiologybased measures as well as for time to PSA progression. Time to initiation of further cytotoxic therapy was prolonged by 9.8 months likely because of the delayed progression with tasquinimod treatment. However, this was not the case for more subjective outcomes such as time to opiate use for cancer pain, time to tumorrelated pain progression, and time to QoL deterioration, all of which were better in the placebo group. The most common AEs over-represented in the tasquinimod group included the types of events that are also commonly seen as signs of cancer progression and general health deterioration and thus may have contributed to the unfavorable outcome of symptomatically assessed end points.
Assessing clinical benefit in mCRPC is challenging, given the heterogeneous nature of the disease and differential effects of subsequent therapy on traditional end points, such as OS and postprogression time-to-event end points.
23 PCWG2 guidelines on defining disease progression 7 have been adopted as the standard primary efficacy measure in most recent clinical trials in mCRPC, and there is widespread interest in the use of PCWG2-defined rPFS as a surrogate end point of survival benefit. A recent analysis of the phase III COU-AA-302 (Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer) trial demonstrated a significant correlation between rPFS and OS. 22 However, the lack of correlation between rPFS and OS in this study and in other phase III studies in mCRPC [24] [25] [26] illustrates that significant improvements in rPFS may not always translate into longer-term survival benefit.
Among several possible explanations for the lack of OS benefit in this study, one contributory factor may be the availability of more effective salvage therapies that prolong OS treatment after the study, 27 many of which were not widely available at the time of the phase II study. The current availability of such agents (eg, abiraterone and enzalutamide) may have had an impact on the course of disease because patients in the placebo group gained access before those in the tasquinimod group on account of their earlier withdrawal from study treatment. Indeed, post-treatment use of abiraterone and enzalutamide was more common among patients in the placebo group. Furthermore, baseline characteristics suggest a more aggressive cancer population in the tasquinimod arm as indicated by an imbalance in median time since diagnosis and baseline Visual Analog Scale score for tumor-related pain. It may also be that the survival results were influenced by a combination of the relatively modest effect on rPFS and other confounding factors, suggesting that tasquinimod may not have sufficient efficacy as a single agent to have an impact on long-term OS.
Further study of predictive biomarkers of tasquinimod efficacy may be warranted to determine whether certain subgroups will derive an OS advantage. Data from the phase II trial suggested that men with low baseline thrombospondin-1 levels derived the greatest benefit from tasquinimod. 16 Because tasquinimod is www.jco.org known to increase this antiangiogenic marker in preclinical tumor models, 28 there may be a mechanistic basis for further examination of predictive biomarkers identified in this study. Preclinical evidence also suggests that tasquinimod has immunomodulatory activity, shown as an inhibitory effect on myeloid-derived suppressive cells and M2-polarized tumor-associated macrophages. 13 Identification of a potential immunologic biomarker will help with patient selection and determination of the most rational combination strategy for developing S100A9 inhibitors.
The tolerability of tasquinimod was good overall, and the vast majority of patients were able to escalate to the maximum 1-mg/day dose according to the predefined schedule. Dose interruptions or reductions were infrequent, and the overall safety profile was consistent with that observed in the phase II study. Tasquinimod was associated with a higher rate of withdrawals as a result of AEs. GI and musculoskeletal disorders occurred at a slightly higher frequency with tasquinimod, as seen in the phase II study. The overall incidence of cardiovascular events was low but, as observed previously, 15,16 was slightly higher with tasquinimod. This higher rate of cardiovascular events may have contributed to the lack of survival benefit due to early drug discontinuation. However, treatment-related deaths were not increased with tasquinimod, suggesting lack of efficacy rather than toxicity as the main contributing factor.
In conclusion, this phase III study confirmed that tasquinimod improved rPFS in patients with mCRPC compared with placebo. This benefit did not translate into an improvement in OS. The tolerability profile of tasquinimod was consistent with that in previous studies. On the basis of the lack of OS benefit observed in this study, further clinical development of tasquinimod in this patient population was not pursued. 
